If it is impossible to make a selection at this point, you may want to consider scheduling an additional interview or conducting additional reference checks. Do not interrupt too soon. Can you set up a computer spreadsheet using Excel? If this is the case it should be noted. Contact Staff Employee for information. It creates a pool of applicants. When the determination is made, applications are either scored for experience and training or candidates are notified of eligibility to participate in the next level of exams. The Employment Manager in Human Resources coordinates the hiring process for classified employees; to initiate a search, you must submit a Request to Hire form and an updated position description. STEP 2: INDEPENDENT RESEARCH BY SUPER LAWYERS Our research department evaluates each lawyer in the candidate pool based on these 12 indicators of peer recognition and professional achievement: Bar and/or professional activity Pro bono and community service These indicators are not treated equally; some have a higher maximum point value than others. It puts lawyers on our radar for further research and evaluation, and awards points in our rating system.
Now, 20717 is our first bispecific antibody to simultaneously engage two T cell checkpoint targets to activate T cells against different tumor types. Now, we believe this dual checkpoint approach and these dual checkpoint bispecific antibodies have the potential to be better than combination therapies by improving selectivity and by eliminating the need for multiple checkpoint antibodies to be administered. this pageAnd we plan to initiate trials for XmAb20717 also in 2017. I’ll also give a brief update on our partnerships. As I mentioned a few moments ago, we started working with Novartis on the development of 14045 and 13676. In addition, the collaboration with them goes beyond these two programs. We’ll also apply our XmAb bispecific Fc domain to Novartis’ antibodies in four different Novartis antibody programs; for one of those programs we may elect to share in cost and US profits in lieu of US royalties, too. In addition, Novartis will receive a non-exclusive license to use our other XmAb FC technologies, specifically our Cytotoxic, Xtend and immune inhibitor Fc domains in up to 10 molecules. Now, like our other partnerships that leverage the plug-and-play nature of our XmAb domain, this additional portion of our collaboration with Novartis, broadens the impact of our technology with little to no research commitment by Xencor.
For the original version including any supplementary images or video, visit Edited Transcript of XNCR earnings conference call or presentation 2-Aug-16 8:30pm GMT